Berlin, Germany – September 2025 – StratifAI, the AI biomarker company for precision oncology, has secured €12.5 million in an oversubscribed funding round. The funding will accelerate the clinical validation of its multimodal AI biomarker discovery platform, Polaris™. The round was led by Picus Capital, with co-lead Alven, alongside Heliad, Rubin Ritter, Lars Langusch, and Jens Begemann. Existing backers Debiopharm, Arve Capital, Christoph Haarburger also joined, deepening their commitment to StratifAI’s vision.
Despite advances in cancer care, biomarker discovery remains slow, costly, and limited in scope, leaving vast opportunities untapped. StratifAI’s fully digital, AI‑driven approach is designed to accelerate biomarker discovery, reduce costs, addressing one of the largest unmet needs in oncology.
Redefining Biomarker Discovery
What once demanded costly, specialized techniques, Polaris™ now achieves from routine histology – delivering spatial insights into tumors at a scale not seen before. By integrating H&E histology with RNASeq gene expression data, the platform instantly links spatial tumor signals to patient outcomes: eliminating additional testing, reducing costs, and revealing new prognostic and predictive insights. The company sources tumor samples, generates high-quality data, and expands a growing portfolio of spatial biomarkers while building a comprehensive multimodal reference dataset. StratifAI’s first product, Polaris™ Breast, is designed to assess the risk of breast cancer recurrence.
The newly secured capital will accelerate clinical validation of Polaris™ Breast and advance regulatory approvals in both Europe and the United States. StratifAI is building collaborations with leading oncology institutions and pharmaceutical companies to generate the large‑scale clinical evidence required for guideline inclusion and to drive real‑world adoption.
Currently, StratifAI is expanding its world-class team and global footprint. This strategic expansion uniquely positions StratifAI to lead the development of the next generation of cancer biomarkers. Its fully digital, AI‑driven approach is set to unlock one of the largest untapped markets in cancer diagnostics by redefining how biomarkers are developed and delivered.
